The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812
Abstract
INTRODUCTION: CT1812 (zervimesine) is an orally dosed modulator of the sigma‐2 receptor (S2R) currently in clinical development for the treatment of Alzheimer's disease (AD). CT1812 has been shown in preclinical and early clinical trials to selectively prevent and displace binding of amyloid beta oligomers from their synaptic receptors and has improved cognitive function in animal models of AD. METHODS: SEQUEL (NCT04735536) is a completed Phase 2, randomized, placebo‐controlled 4‐week crossover trial in adults with mild‐to‐moderate AD that investigated the effect of CT1812 on safety, synaptic function using quantitative electroencephalography (qEEG), and biomarkers. CT1812 improved established qEEG markers of spontaneous brain activity, suggesting improved neuronal and synaptic function. In the present study, cerebrospinal fluid (CSF)‐based tandem mass tag mass spectrometry (TMT‐MS) was performed on participant samples to investigate proteomic effects and identify potential biomarkers of CT1812. RESULTS: Biomarkers found through proteomics analyses to be significantly differentially abundant in CT1812‐ versus placebo‐treated participants supported pathway engagement and proof of mechanism for CT1812. Impacted proteins support a role for CT1812 at synapses, in vesicle trafficking, and in lipoprotein biology. Biomarkers correlated with the previously reported improvements in qEEG‐based functional connectivity (inferred through alpha band Amplitude Envelope Correlations) with CT1812 treatment were also identified and may be potential early surrogate biomarkers of efficacy for CT1812. The processes and functions supported by biomarkers were congruent with those previously revealed in CSF proteomics analyses from phase 1 and 2 AD clinical trials with CT1812. DISCUSSION: After 1 month of treatment, the identification of biomarkers supporting pathway engagement, the replication of biomarker findings from prior trials, and the discovery of molecular correlates of improved functional connectivity with CT1812 treatment bolster support for and expound upon the mechanism of action for CT1812 in displacing Aβ oligomers at neuronal synapses, as well as underscores the CT1812 relevance to AD. Highlights: Exploratory proteomics identified candidate CSF biomarkers of CT1812 in SEQUEL. Molecular correlates of functional brain connectivity (qEEG) were identified. Proteins impacted by 1 month CT1812 treatment support target engagement. Pharmacodynamic changes found in synapse, immune, vesicle, and lipoprotein biologies. SEQUEL proteomics findings replicated previous trial findings with CT1812.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previously, only CSF proteomics analyses have been reported to assess the biological impact of zervimesine in AD participants.
“Previously, only CSF proteomics analyses have been reported to assess the biological impact of zervimesine in AD participants [5, 6, 26].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Johnson, E. C. B., Carter, E. K., Dammer, E. B., Duong, D. M., Gerasimov, E. S., Liu, Y., Liu, J., Betarbet, R., Ping, L., Yin, L., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00999-y · Cited by 561
Self-citationHigginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Hurst, C., Glass, J. D., Factor, S. A., Johnson, E. C. B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz9360 · Cited by 367
Self-citationTumbarello, D. A., Waxse, B. J., Arden, S. D., Bright, N. A., Kendrick-Jones, J., & Buss, F. (2012) · Nature Cell Biology · doi:10.1038/ncb2589 · Cited by 301
What are lipoproteins doing in the brain?
Wang, H., & Eckel, R. H. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.10.003 · Cited by 234
Izzo, N. J., Staniszewski, A., To, L., Fa, M., Teich, A. F., Saeed, F., Wostein, H., Walko, T., Vaswani, A., Wardius, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111898 · Cited by 180
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
Colom-Cadena, M., Toombs, J., Simzer, E., Holt, K., McGeachan, R., Tulloch, J., Jackson, R. J., Catterson, J. H., Spires-Jones, M. P., Rose, J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02679-6 · Cited by 44
Self-citationEHD1 is a synaptic protein that modulates exocytosis through binding to snapin
Wei, S., Xu, Y., Shi, H., Wong, S.-H., Han, W., Talbot, K., Hong, W., & Ong, W.-Y. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.07.014 · Cited by 22
Flagged first, then by citations
Research works printed but not linked: 45
- 10.1002/alz.12302 · DOI · Paper page
- 10.1186/s40035‐023‐00358‐w · DOI · Paper page
- 10.1016/j.nbd.2024.106575 · DOI · Paper page
- 10.1002/alz.14152 · DOI · Paper page
- 10.1371/journal.pone.0111899 · DOI · Paper page
- 10.1007/s40120‐019‐00169‐0 · DOI
- 10.1016/j.neurobiolaging.2019.09.008 · DOI
- 10.1186/s13195‐020‐00588‐4 · DOI · Paper page
- 10.2147/NDT.S433207 · DOI
- 10.1016/j.clinph.2004.01.001 · DOI
- 10.1007/s10548‐023‐00968‐7 · DOI
- 10.1038/nrn3801 · DOI
- 10.1038/nn.3101 · DOI · Paper page
- 10.14283/jpad.2024.154 · DOI
- 10.1016/j.neurobiolaging.2017.05.017 · DOI
- 10.1186/s13024-024-00757-1 · DOI
- 10.1038/s41588‐018‐0311‐9 · DOI · Paper page
- 10.1016/j.cbi.2023.110601 · DOI
- 10.1016/j.transci.2021.103164 · DOI
- 10.1002/alz.12531 · DOI
- 10.1515/hsz‐2012‐0103 · DOI
- 10.1016/j.freeradbiomed.2014.12.002 · DOI
- 10.1038/srep29078 · DOI
- 10.1186/s40478‐022‐01398‐5 · DOI
- 10.1186/s13024‐021‐00465‐0 · DOI
- 10.1093/hmg/ddg357 · DOI
- 10.1007/s11065‐014‐9249‐6 · DOI · Paper page
- 10.1016/j.neurobiolaging.2011.10.013 · DOI
- 10.1186/s13195‐020‐00632‐3 · DOI
- 10.3389/fnagi.2023.1291881 · DOI
- 10.1016/j.clinph.2019.09.014 · DOI
- Di Caro V, 2025, Biomarkers in CNS drug discovery, drug development, and clinical implementation, 10.1002/9783527844678.ch7 · DOI
- 10.1038/s41419‐018‐0410‐7 · DOI
- 10.1038/ncomms9836 · DOI
- 10.1017/S0016672319000090 · DOI
- 10.1038/srep31158 · DOI
- 10.1016/j.tcb.2010.10.003 · DOI · Paper page
- 10.1091/mbc.e05‐01‐0076 · DOI · Paper page
- 10.1074/jbc.M009913200 · DOI · Paper page
- 10.1016/j.celrep.2013.12.006 · DOI · Paper page
- 10.1111/j.1600‐0854.2011.01213.x · DOI
- 10.1016/j.celrep.2019.10.039 · DOI
- 10.1016/j.celrep.2022.111200 · DOI
- Furniss SK, 2014, Automatic gene prioritization in support of the inflammatory contribution to Alzheimer's disease, AMIA Jt Summits Transl Sci Proc, 2014, 42
- 10.1002/dad2.12001 · DOI · Paper page
Cited by
Sorted by citations
Di Caro, V., Cho, E., Thiel, J., Lizama, B. N., Koel-Simmelink, M. J. A., Pandey, K., Duong, D., Seyfried, N. T., Grundman, M., Teunissen, C. E., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02025-4 · Cited by 1
Self-citation
Metadata
- Authors
- Di Caro, V., Cho, E., North, H. A., Caldwell, J., Pandey, K., Duong, D., Grundman, M., de Haan, W., Vijverberg, E. G., Teunissen, C. E., Caggiano, A. O., Seyfried, N. T., & Hamby, M. E.
- Affiliations
- Research Cognition Therapeutics Pittsburgh Pennsylvania USA
- Systems Biology Emtherapro Inc Atlanta Georgia USA
- Department of Biochemistry Emory University School of Medicine Atlanta Georgia USA
- Global R&D Partners, LLC San Diego California USA
- Department of Neurology Alzheimer Center VU University Medical Center Amsterdam The Netherlands
- Department of Laboratory Medicine VU University Medical Center Amsterdam The Netherlands
- ORCID
- Hamby, Mary E.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2025-04
- Volume
- 11
- Issue
- 2
- ISSN
- 2352-8737
- PMC
- PMC12178945
- Cited by
- 2
- References
- 7
- Language
- en
- Funders
- National Institute on Aging (RF1AG058710)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
